Under construction – not a live service
Sign in
Taking people in EgyptPhase 3

Tests rosuvastatin for depression in adults with major depressive disorder

Tests whether rosuvastatin, a cholesterol drug, may help adults with major depression.

Key facts

Who runs it
Ain Shams University
Where
Cairo, EgyptSee the site
Trial code
Registry title
Efficacy of Statins Among Major Depressive Disorder
Status
Recruiting
Phase
Phase 3
People taking part
145 people, planned
Started
1 Oct 2022
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Rosuvastatin 10 mg tablet.
  • Sertraline Pill
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 to 45 with current major depression of mild to moderate severity. It tests whether rosuvastatin 10 mg helps depression.

Age
20 to 45 years
Sex
Men and women can join.
Disease stage
Current major depressive disorder (MDD), confirmed by a structured clinical interview, with a MADRS depression score of 7 to 34 (mild to moderate depression).
Earlier treatment
People already treated for depression need a stable treatment for at least 2 weeks before joining. People currently taking statins, corticosteroids or other immunomodulatory medicines cannot join.

Main reasons for not taking part

  • Current or past psychotic disorder
  • Past bipolar I or II disorder or alcohol dependence
  • Acute or unstable general medical illness
  • Allergy or intolerance to the study medicines
  • Current pregnancy or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • aged between 20 and 45 years
  • diagnosis of current MDD, verified using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient version (SCID-I/P)
  • The Montgomery Asberg Depression Rating Scale (MADRS) score of 7 to 34, indicating mild to moderate depression
  • the ability to give informed consent and to comply with standard procedures
  • Males and females; and
  • Stable pharmacological treatment for at least 2 weeks prior to enrolment (changes to medication dose or frequency of therapy excepted) if currently being treated

Who cannot take part

  • Current regular use of statins, corticosteroids, or any other immunomodulatory agents; and
  • lifetime or current SCID-I/P diagnosis of a psychotic disorder
  • lifetime SCID-I/P diagnosis of bipolar I or II disorder or alcohol dependence
  • acute or unstable systemic medical disorder
  • history of intolerance or allergy to study medications
  • inability to comply with the requirements of informed consent or the study protocol
  • Current pregnancy or breast feeding
  • Females on Contraception

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 45 years old?

Where in Egypt

  • El-Demerdash hospitalCairo, EgyptContact: Silvana NaderTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat MDD in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are:

Read full original descriptionShow less

Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( MDD )? What medical problems do participants have when taking drug ABC?

Participants will:

Take Rosuvastatin 10 mg every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Report any side effects for Rosuvastatin 10 mg and reassess the severity of depression using The Montgomery Asberg Depression Rating Scale (MADRS)

The 2 groups in the trial

  • The Control GroupOther group

    The Control Group will receive the standard treatment of depression including SSRI (Sertraline) only

  • The Interventional groupTreatment being tested

    the interventional group will receive the standard treatment of depression including SSRI (Sertraline) in addition to the10 mg/day rosuvastatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Efficacy of Statins in Management of Major Depression Disorder (MDD) Among Adult Patients Attending the Outpatient Clinics of El Demerdash Hospital.
Plain-language title
Tests rosuvastatin for depression in adults with major depressive disorderGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06698666, who can take part
Record updated
4 November 2026